T
Tubulis
Generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology
About Tubulis
Tubulis is a biotechnology startup that operates in the pharmaceutical industry, specifically in the development of next-generation Antibody-Drug Conjugates (ADCs). These are targeted drugs designed to deliver cytotoxic agents directly to cancer cells, thereby increasing the effectiveness of treatment while reducing side effects. Tubulis' unique approach aims to expand the therapeutic potential of these protein-drug conjugates by increasing design flexibility and overcoming constraints of toxicity, efficacy, and indication.
The company's business model revolves around the development of new ADCs to fill its pipeline and partnering with other pharmaceutical companies to bring these drugs to market. One of its key partnerships is with Oncoteq, for the development of TUB-010, a CD30-targeting ADC. Tubulis has also entered into a strategic license agreement with Bristol Myers Squibb, a leading pharmaceutical company, to develop next-generation ADCs for cancer treatment.
Tubulis generates revenue through these strategic partnerships and licensing agreements, where it receives upfront payments, milestone payments based on the progress of drug development, and potential royalties from the sale of any approved drugs. The company also publishes research articles, such as the one in Molecular Cancer Therapeutics, highlighting the advantages of its proprietary P5/Tubutecan platform.
The company's primary clients are other pharmaceutical and biotechnology companies interested in developing and commercializing novel ADCs. By offering a unique and flexible approach to ADC design, Tubulis is well-positioned to serve a significant market need in the oncology drug development space.
Source: Dealroom company dataKnowledge graph
Market map
Rare Disease Therapeutics & Technologies Landscape
Market map
Computational Biology & Chemistry startups in Europe
Market map
AI x Drug Development in India
Nov 16, 2026
Unicorn list
Biotech & Life Sciences unicorns
Unicorn list
Unicorns in Germany
Analysis
European health companies to watch in 2026
Oct 7, 2026
Open roles
Tubulis in the Planegg ecosystem
The Tubulis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
Seventure Partners
Coparion
HTGF
BioMedVC
Bayern Kapital
OCCIDENT
Evotec
Andera Partners
FundPlus
Deep Track Capital
Frazier Life Sciences
EQT Life Sciences
Nextech Invest
Series B and later12 investors entered at this stage
Nextech- ZHZweiKa Holding
- GHGreendale Holding
- SHSouth Lake Holding
EQT Ventures
Fund+- SHScience Holding
- HHHSM Holding
- LELeXito
Venrock
Wellington Management
Ascenta Capital
Source: Dealroom Talent Intelligence.
Patents
13 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Tubulis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Gilead acquires Tubulis (May 2026)